Athira Pharma has acquired exclusive rights to develop and commercialize lasofoxifene for metastatic breast cancer.
The Phase 3 clinical trial for lasofoxifene is currently over 50% enrolled, with data expected in mid-2027.
The company secured a significant financing of up to $236 million to support the development of the Phase 3 program.
Exclusive License Acquisition
Acquired exclusive global license (excluding Asia and certain countries in the Middle East) from Sermonix Pharmaceuticals for lasofoxifene development.
Phase 3 Trial Progress
Phase 3 ELAINE-3 trial is over 50% enrolled, on track for data readout in mid-2027.
Financial Support
Secured $90 million upfront financing with potential additional $146 million through warrants for key milestones.
- Lasofoxifene shows promise in treating ESR1-mutant metastatic breast cancer patients.
- Potential to provide meaningful combination efficacy with tolerability benefits.
- Expected to establish lasofoxifene as a preferred endocrine therapy for certain breast cancer patients.
Athira Pharma's acquisition of lasofoxifene's development rights and significant financing mark a pivotal moment for the company, poised to revolutionize the treatment of metastatic breast cancer.